MYC and prostate cancer: Since low AR-A tumors were predicted to be less sensitive to androgen-deprivation therapy and more likely to develop metastatic disease after initial local therapy34, we next asked whether a high MYC transcriptional activity allows for the identification of a more aggressive subtype of treatment-naïve primary prostate cancer.